<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458315</url>
  </required_header>
  <id_info>
    <org_study_id>Cis/Gem/Tax +/- Avastin</org_study_id>
    <nct_id>NCT00458315</nct_id>
  </id_info>
  <brief_title>Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor</brief_title>
  <official_title>Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of Cisplatin, Paclitaxel,
      Gemcitabine +/- Avastin (Bevacizumab) in patients with unknown primary tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, all patients will be randomly assigned to one of two
      treatment arms:

      Arm A: Cisplatin, Paclitaxel and Gemcitabine

        -  Cisplatin 75 mg/m2 IV infusion, Day 1

        -  Paclitaxel 175 mg/m2 IV infusion, Day 1

        -  Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8

      Arm B: Cisplatin, Paclitaxel, Gemcitabine and Avastin (Bevacizumab)

        -  Cisplatin 75 mg/m2 IV infusion, Day 1

        -  Paclitaxel 175 mg/m2 IV infusion, Day 1

        -  Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8

        -  Bevacizumab 7,5 mg/m2 IV infusion, Day 1

      Patients will be stratified by number of metastatic sites (one versus two or more) and the
      level of Lactate Dehydrogenase (normal versus high).

      The regimens will be repeated every 21 days.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    never been started
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Unknown Primary Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin (Bevacizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unknown primary tumors

          2. ECOG performance status 0-1

          3. Adequate kidney, liver and bone marrow function

          4. No prior chemotherapy

          5. Life expectancy &gt; 3 months

        Exclusion Criteria:

          1. The following specific syndromes:

               -  Squamous carcinoma limited to cervical glands

               -  Women with adenocarcinoma isolated to axillary nodes

               -  Women with adenocarcinoma isolated to peritoneal involvements

               -  Young men (&lt;55 years) with growing mid-line tumors where a germ cell tumor could
                  be expected

               -  Neuroendocrine carcinomas

          2. Tumor located close to major blood vessels and judged to possess a high risk of
             serious bleeding

          3. Any significant cardiac disease

          4. Clinically significant peripheral vascular disease

          5. History of myocardial infarction or stroke within 6 months

          6. Evidence of coagulopathy

          7. Use of ASA, NSAIDs or clopidogrel

          8. Pregnancy or breast feeding

          9. Ongoing therapeutic anti-coagulation

         10. Hypertension with blood pressure &gt; 150/100 mmHg

         11. Brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gedske Daugaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Dept of Oncology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2007</study_first_submitted>
  <study_first_submitted_qc>April 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Gedske Daugaard</investigator_full_name>
    <investigator_title>dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

